CureVac N.V. (CVAC)
| Bid | 2.74 |
| Market Cap | 622.45M |
| Revenue (ttm) | 542.68M |
| Net Income (ttm) | 110.51M |
| EPS (ttm) | 0.5 |
| PE Ratio (ttm) | 5.55 |
| Forward PE | -8.07 |
| Analyst | Hold |
| Ask | 3.48 |
| Volume | 1,065,684 |
| Avg. Volume (20D) | 825,689 |
| Open | 2.93 |
| Previous Close | 2.98 |
| Day's Range | 2.72 - 2.93 |
| 52-Week Range | 2.21 - 5.28 |
| Beta | 2.53 |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...
Analyst Forecast
According to 3 analyst ratings, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 260.36% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · accessnewswire.com
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top InnovatorsCureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of t...
2 months ago · seekingalpha.com
CureVac: Latest GBM Data Bodes Well For Next Program Check PointCureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVG...